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Neonates are defined as infants younger than 28
days old, and in general many transfusion protocols are
standardized to represent infants younger than 4 months
of age. Often the distinction is made between pre-
mature neonates and term neonates, and institutional
protocols may be established on the basis of age or birth
weight. When this is important in terms of transfusion
protocols, premature neonates, neonates, and infants
will be described separately.
Indications for Neonatal and Infant Platelet
Transfusions
Healthy term infants are born with the same platelet
count as adults, whereas premature infants may have
platelet counts that are on the lower end of the adult
normal range (150 × 109/L to 450 × 109/L). When the
platelet count is less than normal, this is an indication
for investigation and possibly treatment that may
include platelet transfusions. Many disorders are asso-
ciated with thrombocytopenia in neonates, and an
investigation for infections, drug exposures, auto-
immunity or alloimmunity, thromboses, neoplasms, and
genetic conditions is important for the evaluation of the
need for treatment or transfusion.
The degree of thrombocytopenia in newborns
varies, although thrombocytopenia is the most
commonly reported hematologic abnormality in
neonatal intensive care units (NICU). According to
Castle et al.,1 75 percent of sick neonates will have a
transient thrombocytopenia by day 2 of life,which will
nadir by day 4 and return to normal counts by day 10 of
life in 86 percent of neonates. These neonates may not
require a transfusion. However, approximately 50
percent of hospitalized neonates will have a platelet
count decrease to less than 100 × 109/L,and 20 percent
will have a decrease to less than 50 × 109/L.1,2 These
neonates may require platelet transfusion. There is
ongoing controversy over the indications, trigger, and
dosing for platelet transfusions in these patients,and this
presents a clinical challenge owing to the limited data
from controlled clinical trials.
Platelet Transfusion Guidelines
The decision to transfuse is often considered in
terms of treatment of severe bleeding in an unstable
neonate or prophylaxis to prevent bleeding in a more
stable neonate. The AABB Pediatric Hemotherapy
Committee, by developing a practice consensus, was
one of the first groups to develop guidelines for
neonatal platelet transfusion for the purposes of
auditing.3 AABB members who were surveyed for the
study noted that the platelet transfusion criteria for sick
premature infants was too liberal at 100 × 109/L in
contrast to the medical practice at many institutions to
transfuse at less than 50 × 109/L. After that consensus
survey, other published guidelines emerged for infants.
These guidelines recommended that stable neonates
with a platelet count of less than 50 × 109/L with active
bleeding or an invasive procedure with production
failure may require platelet transfusion. Neonates with
platelet counts less than 30 × 109/L as a result of failure
of platelet production,but no identified bleeding or risk
of bleeding,may also require platelet transfusion. In rare
instances, guidelines for neonates may more closely
resemble guidelines for older children and adults, in
whom transfusions are recommended for platelet
counts of 5 to 10 × 109/L. A sick unstable neonate may
be transfused if the platelet count drops below 100 ×
109/L with active bleeding or when an invasive
procedure is anticipated in patients with sepsis,
disseminated intravascular coagulation, or other
mechanism of platelet consumption.4,5
The sick premature infant is at especially high risk
for an intracranial hemorrhage (ICH) from a low platelet
count or poor platelet function. These infants (younger
than 37 weeks) have decreased plasma coagulation
Neonatal and infant platelet
transfusions
D.A. SESOK-PIZZINI AND D. FRIEDMAN
R E V I E W
16 I M M U N O H E M A T O L O G Y, VO L U M E 2 4 , N U M B E R 1 , 2 0 0 8
D.A. SESOK-PIZZINI AND D. FRIEDMAN
proteins and poor platelet function compared with
older children and adults. In addition, these premature
neonates have an underdeveloped subependymal
matrix that puts them at increased risk for an ICH,
particularly in the first 3 to 5 days after birth.6 A
multicenter prospective, randomized controlled trial
investigated whether early use of platelet concentrates
reduced the incidence or extension of ICH in sick
neonates.2 This study concluded that neonates who
were transfused when their platelet count decreased to
less than 150 × 109/L did not show a significant
difference in a new, or extension of an, ICH compared
with the untransfused control group. Infants in the
control group received a transfusion when their platelet
counts were less than 50 × 109/L or the infant was
bleeding. However, the study group did show an overall
reduction in the use of plasma and RBCs compared with
the controls. This study would suggest that prophylactic
transfusion at a higher trigger value does not impact
clinical outcome for risk of ICH.
More recent guidelines for platelet transfusion
recommended a lower trigger value of less than 20 ×
109/L or 30 × 109/L for platelet transfusions in term
infants.7,8 The rationale for the lower trigger value is
that most serious bleeding caused by thrombocyto-
penia occurs in the first days of life. Therefore,patients
severely thrombocytopenic from sepsis or necrotizing
enterocolitis beyond the first few days of life rarely have
major hemorrhage. Other recommendations given are
a higher trigger level of less than 50 × 109/L for patients
who are at highest risk for hemorrhage caused by
clinical instability or very low birth weight (less than
1000 g). Lastly, a trigger value of less than 50 × 109/L
would be indicated for neonates with major bleeding
from a pulmonary, gastrointestinal, or renal source. In
reviewing studies of contemporary platelet transfusion
practice in neonates, Murray and Roberts9 noted that
there were a variety of platelet triggers used in different
neonatal intensive care units and that thrombo-
cytopenic neonates were 10 times more likely to die
than neonates who did not receive transfusions. Del
Vecchio et al.10 also concluded that neonates who
receive more than four platelet transfusions had a risk
of death 29.9 times that of neonates who did not
receive a transfusion. This is most likely attributable
to the underlying disease and severity of the
clinical condition resulting in the thrombocytopenia.
The lack of definitive criteria for prophylactic
platelet transfusions in this population caused the
authors to conclude that alternative treatments for
thrombocytopenia are needed. These treatments may
include hemopoietic growth factors. Clinical trials are
needed to investigate the use of recombinant
thrombopoietin to increase platelet production in
thrombocytopenic neonates.
Selection of Platelet Components
Platelet components may be platelet pheresis
(single-donor platelets or apheresis platelets) or platelets
(whole blood–derived platelets). Both platelet compo-
nents are currently stored for 5 days,but they differ with
respect to their platelet counts and risk for adverse
effects. Apheresis platelets are prepared using an
automated collection device from a single donor and
collected in volumes of 200 to 400 mL,which includes
platelets, donor plasma, anticoagulants, leukocytes, and
a few RBCs. Apheresis platelets that are leukocyte
reduced should contain less than 5 × 106 WBCs and
greater than 3 × 1011 platelets. In contrast,whole blood–
derived platelets are prepared from centrifuged whole
blood to a final concentrated volume of about 50 mL.
Whole blood–derived platelets also contain donor
plasma, anticoagulant, leukocytes, and RBCs. Whole
blood–derived platelets that are leukocyte reduced have
less than 5 × 106 WBCs and greater than 5.5 × 1010
platelets.11,12
The standard dose for neonates is based on body
weight and is the same for either apheresis platelets or
whole blood–derived platelets at 5 to 10 mL/kg for an
increase of 50,000/ L in the platelet count. Some
centers calculate doses based on random donor units or
their equivalents.13 In some institutions, dose is based
on the platelet count from the component, and the
aliquot given to the neonate is adjusted accordingly. If
apheresis platelets are used for platelet transfusions, the
platelets may be separated into smaller aliquots to
decrease donor exposures and platelet wastage. The
aliquot or platelet syringe is considered an open system,
and the platelets will expire within 4 hours. As long as
the separation into a syringe is done with a sterile
connecting device, the expiration time of the “mother
unit” should not change.11,12 However, the viability of
the platelets may be affected by altering the volume
within the storage bag. Transfusion services preparing
aliquots from apheresis platelets should be aware of
the manufacturer requirements for platelet storage.
This practice of providing platelet aliquots from
apheresis platelets is controversial because of the
accuracy of the platelet component in volume only and
not in final platelet concentration.
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Both platelets and apheresis platelets require the
same storage conditions, but the testing for bacterial
contamination remains disparate between the two
components. Platelet pheresis components routinely
undergo sampling for bacterial contamination via
culture methods. In the case of whole blood–derived
platelets,bacterial testing is often done by pH testing or
other methods less sensitive than those used for
apheresis platelets. In the future, changes in standard
pooling practices for whole blood–derived platelets and
improved testing methods may provide the most
sensitive and specific bacterial testing for both platelet
components.
Risk of Platelet Transfusion in the Neonate
and Infant
The infectious risk for each component may be
perceived as different for neonatal transfusions because
of the ability to transfuse many more aliquots from
apheresis platelets compared with whole blood–derived
platelets. This provides a mechanism for donor limi-
tation with regard to platelet transfusion and therefore
exposes the neonatal patient to less infectious risk.
Strict adherence to sterile technique for the aliquot
preparation is necessary to avoid bacterial contami-
nation during the aliquot manufacturing process.
In addition to infectious risk, the neonate is
exposed to other risks of transfusion with the use of
either whole blood–derived platelets or apheresis
platelets. Hemolytic risks from ABO-incompatible
plasma may be significant in the neonate owing to
small blood volumes, although a precise risk estimate
for neonates is not available. Accrediting agencies such
as the College of American Pathologists and AABB
require protocols to ensure safety ofABO-incompatible
transfusions.11,14 If possible, infants should receive
only platelets that are ABO-group specific or
compatible with the infant’s plasma. WhenABO-group
specific or compatible platelets are not available, the
institution may elect to modify the component to
remove plasma and reduce the risk for hemolysis.
These modifications include saline replacement,
volume reduction, and washing.12 Depending on the
institution, all or some of these modifications may be
available. With each modification, less platelets are
recovered and some will become activated,which can
adversely affect the efficacy of the transfusion. Until
the platelet supply is sufficient for demand, these
modifications are necessary for platelet transfusion
support in the neonate.
Neonates may require additional special compo-
nents as a result of the underlying disease causing the
thrombocytopenia. Neonates with neonatal alloimmune
thrombocytopenia will require special platelets that lack
the platelet-specific antigen implicated in the disease.
These antigen-negative platelets may be available from a
maternal source or another allogeneic donor. It is also
conceivable that maternal HLA antibodies passively
acquired in the neonate may impact response to platelet
transfusions. Transfusion-transmitted CMV is of concern
in the premature neonate because of the risk of serious
CMV disease in premature infants. Components with
reduced risk for CMV transmission are either negative
when tested for CMV antibodies or leukocyte reduced.
Patients at risk for severe CMV infection include those
with congenital immunodeficiency disorders or AIDS,
hematopoietic progenitor cell transplant recipients,
organ allograft transplant recipients, premature infants
during infancy, cancer patients undergoing intense
chemotherapy, and recipients of intrauterine trans-
fusion.5 Irradiation of platelet components to prevent
transfusion-associated GVHD is also indicated for
premature infants. The requirement for CMV-negative
and irradiated platelets in the term neonate is more
controversial.
Protocols for Neonatal and Infant Platelet
Transfusion at The Children’s Hospital of
Philadelphia
At The Children’s Hospital of Philadelphia (CHOP),
we support a very large infant intensive care unit with
60 NICU and 15 cardiac intensive care unit (CICU) beds.
Our NICU and CICU neonates and infants receive
irradiated, “CMV-safe” leukocyte-reduced apheresis
platelets when a transfusion is required. ABO and D
type-specific or compatible apheresis platelet aliquots
are selected. IfABO group-specific or compatible is not
available, saline replacement is performed to remove
ABO-incompatible plasma. Saline suspension requires
centrifugation to remove plasma followed by the sterile
addition of 0.9% normal saline, usually back to the
starting volume. These components are placed back on
the rotator for approximately 1 hour to ensure proper
mixing. Aliquots are manufactured in the blood bank
with the use of a sterile connecting device. The syringe
aliquots expire within 4 hours as an open system, and
the remaining platelets are stored in the original
container with no change in expiration time. During
blood shortages,whole blood–derived platelets are used
for transfusion. Our present policy calls for irradiation
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of all platelet products in inventory, but it excludes
irradiation of RBC components for term neonates in
surgery unless there is a specific medical indication for
irradiation.
CHOP provides D type–specific or compatible plate-
lets and would recommend RhIG administration in the
event a female neonate with D– RBCs received D+
components. Our policy reinforces concerns raised
with the reported case from Brigham and Women’s
Hospital where an infant, at 17 weeks of age,developed
anti-D from a platelet transfusion. This case report
suggests that only a small amount of D+ RBCs may cause
antibody formation in an infant just beyond 4 months of
age.15 Further data need to be collected to determine
the sensitization risk of D+ platelet transfusion in D–
infants around 4 months of age.
At CHOP, we have surveyed our institutional platelet
triggers in the NICU, and our data are similar to those
published by Del Vecchio et al.,10 who noted a range of
platelet transfusion triggers. Figure 1 displays the platelet
count that immediately preceded the transfusion in 909
platelet transfusion events in our NICU. A trigger platelet
count value of less than 100 × 109/L would account for
about 90 percent of the platelet transfusions ad-
ministered in the CHOP NICU. However, according to
published guidelines, a more stringent trigger value of
less than 50 × 109/L may have been considered in some
of these patients. Figure 2 shows that the majority of
platelet transfusions in neonates occurred in the first
week of life. It appears that the majority of the platelet
transfusions were given in accordance with published
guidelines. As we begin to look at our institutional data
and outcomes, we may better understand the risks and
outcomes of our NICU trigger values,and our guidelines
may change accordingly.
Neonates and infants on extracorporeal membrane
oxygenation (ECMO) are at considerable risk for
thrombocytopenia. Platelets are given at startup and at
circuit change to avoid the thrombocytopenia generally
associated with the procedure as a result of platelets
binding to the tubing or activated within the ECMO
circuit. Additional dilutional effects from the massive
transfusion of RBCs and plasma also factor into the risk
for thrombocytopenia. Approximately 10 to 35 percent
of neonates receiving ECMO will have a hemorrhagic
event.16 Patient platelet counts need to be closely
monitored during ECMO. Adjustments are required to
allow a higher transfusion of platelet dose based on
weight. At CHOP, ECMO infants and neonates are
transfused platelets to a maximum volume of 40 mL/kg.
Conclusions
Neonatal and infant platelet transfusions are given
in a prophylactic or therapeutic setting to thrombo-
cytopenic neonates and infants,either to reduce the risk
of bleeding or for active bleeding. Because thrombo-
cytopenia in a neonate can be caused by a variety of
factors, it is important for the hospital to develop
indications, guidelines, and thresholds for platelet
transfusions. Neonates and infants receiving trans-
fusions are at additional risk for other adverse reactions
to blood products, including infection, immunologic
effects, transfusion-related acute lung injury, and fluid
overload, among others. Institutional protocols should
define the need for irradiation and CMV-negative
components in infants, neonates, and premature
neonates. Standardization of practice, when possible,
allows for better process control and patient
management.
Fig. 1. Frequency distribution of 909 pretransfusion platelet counts in
infants who received platelet transfusions while admitted to The
Children’s Hospital of Philadelphia NICU between July 1,2006,and
June 30, 2007.
Fig. 2. Frequency distribution of patient ages at the time of platelet
transfusion (N = 909) in infants who received platelet transfusions
while admitted to The Children’s Hospital of Philadelphia NICU
between July 1, 2006, and June 30, 2007.
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